REGISTER
Details
Genetic testing is becoming ubiquitous and can identify mutations in over 80 hereditary cancer genes. Each gene causes its own set of cancers, and each gene-cancer association has a distinct risk (penetrance) and age of onset. With over 400 identified gene-cancer associations, it has become impossible for humans to keep up with the latest management strategies. In this talk, we will discuss what role AI has had and will have in assisting physicians in managing these patients who are at high risk of cancer, and thereby help decrease the morbidity and mortality of hereditary cancer.
Agenda:
Join us at 5:30 for snacks, drinks, conversation, and socializing.
6:00 - Main talk(s)
7:00 - 7:30 - Wrap up and hang out some more
7:30 - ? - After Party*
======================================
"Call for Papers"! .. if you have some knowledge to share with the community, please talk to Dave at the next meetup. We'd love to have 1 or 2 talks per meetup lined up for the coming months.
*After Party? .. The meetup is right next to Revelry Brewing. If folks are interested, we can clean up at the CLC and keep the conversation going over a nice local brew.
Speaker
Kevin S. Hughes, MD, Director of Cancer Genetics
Kevin S. Hughes, MD, Director of Cancer Genetics, McKoy Rose Professor of Surgery, Medical University of South Carolina, Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic, and Professor Emeritus, Harvard Medical School
Dr Hughes co-authored the ANSI approved HL7 V3 message to transmit family history data and is the co-creator of CRA Health (Acquired by Volpara), which calculates cancer risk for over 5,000,000 patients each year. He is the Co-Creator of Ask2Me.Org which calculates risk specifically for patients with mutations in cancer susceptibility genes (over 2000 page-views each months) and HereditaryCancer.AI, which uses Graph database technology to illustrate hereditary cancer genes and their related cancers. While continuing an active clinical practice, Dr Hughes is developing software that simplifies the management of patients with mutations in cancer susceptibility genes.
